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The following INS gene mutation was numbered incorrectly:
In Figure 1, Figure 2, and section 6.1, we refer to the
mutation V93L. This should have read as V92L. This does
not affect the numbering of the other mutations, which
remain correct. The corrected versions of Figures 1 and 2 are
presented below. We apologize for this error.
The online version of the original article can be found at http://dx.doi.
org/10.1007/s11154-010-9151-3.
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Fig. 1 Diagrammatic representation of the amino acid sequence of
human preproinsulin (signal peptide–green, B-chain–red, C-peptide–
orange, A-chain–dark blue) indicating sites of mutations identified in
patients with diabetes as well as hyperinsulinemia and hyperproinsu-
linemia. Mutations shown in black disrupt proinsulin folding and/or
disulfide bond formation leading to permanent neonatal diabetesmellitus
(PNDM); mutations in light blue do not impair folding but are associated
with reduced insulin receptor binding potency (hyperinsulinaemia);
mutations in light green are associated with hyperproinsulinaemia and
either impair proteolytic processing to insulin or, in the case of H34D,
aggregation and sorting into dense-core granules of the regulated
secretory pathway. Mutations in pink and purple were found in patients
with a diagnosis of maturity-onset diabetes of the young (MODY) and
type 1b diabetes, respectively. The R55C mutation has been found in
patients with a diagnosis of type 1b diabetes as well as MODY. The
mutations shown in gray (A23S, A23T, L68M and G84R) are rare
variants without functional effects on proinsulin/insulin biosynthesis. The
mutations shown in yellow are recessive mutations that affect insulin
biosynthesis (mutation of the translation initiation Met) or cause the
synthesis of a nonsense protein (Q62X)
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Fig. 2 Summary of human insulin gene mutations and disease
phenotype. The numbers in brackets indicate the number of probands
with that specific mutation. PNDM, permanent neonatal diabetes
mellitus; TNDM, transient neonatal diabetes mellitus; MODY,
maturity-onset diabetes of the young; T1BDM, type 1b diabetes
mellitus
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